Repros Close $15.5M Registered Direct Deal

October 2008
Bioworld Week;10/13/2008, Vol. 16 Issue 41, p2
The article reports on the initiative of Repros Therapeutics Inc. to close a registered direct offering that will provide the company with $15.5 million and the potential for another $10 million. It notes that Repros sold 2.4 million shares to a few of its existing investors, and pricing the shares at $6.50 each. Moreover, the investors can also purchase another $10 million worth of shares priced at the greater of fair market value of $7.80 per share.


Related Articles

  • Repros Looks Inside to Close $15.5M Registered Direct Deal. Morrison, Trista // BioWorld Today;10/6/2008, Vol. 19 Issue 194, p1 

    The article reports on a registered direct offering closed by Repros Therapeutics Inc. in the U.S. in 2008. The offering will provide Repros with $15.5 million and the potential for another $10 million. The company sold 2.4 million shares to a few of its existing investors, pricing the shares at...

  • Financings Roundup.  // BioWorld Today;9/6/2012, Vol. 23 Issue 173, p6 

    The article reports on the decision by Repros Therapeutics Inc. to sell about 2.1 million shares of common stock to several institutional investors for 11 U.S. dollars per share to raise funds for the development of its Androxal and Proellex products.

  • Financings Roundup.  // BioWorld Today;1/30/2012, Vol. 23 Issue 10, p7 

    The article offers information an agreement made by Repros Therapeutics Inc. of The Woodlands, Texas with shareholders to sell common stocks worth 2.4 million shares.

  • Genuine Parts Company GPC. Peters, Josh; Holland, Daniel // Morningstar DividendInvestor;Aug2008, Vol. 4 Issue 7, p14 

    The article provides information on the business operation and stocks performance of Genuine Parts Co. (GPC) in the U.S. It highlights the strategies that GPC employed in maintaining its business relationship to its customers, further emphasizing the 80 years stability of its automotive segment....

  • Stock Movers.  // BioWorld Today;4/26/2011, Vol. 22 Issue 80, p2 

    A chart is presented that shows stock prices of selected companies as of April 25, 2011, which includes Oncothyreon Inc., Pacira Pharmaceuticals Inc. and Repros Therapeutics Inc.

  • Financings Roundup.  // BioWorld Today;2/7/2011, Vol. 22 Issue 25, p4 

    This article reports on the pricing by Repros Therapeutics Inc. of its public offering of 690,000 units at 17.15 U.S. dollars each.

  • MutualFirst in Indiana Facing Activist Challenge, Pressure to Sell. Davis, Paul // American Banker;2/6/2015, Vol. 180 Issue F306, p1 

    The article discusses the move of Ancora Catalyst Fund and Merlin Partners to nominate activist investors Thomas Coley Brady and Timothy McMeekan to join the board of MutualFirst Financial, and cites the proposal of Ancora to MutualFirst to sell itself to a larger bank with higher valued stock.

  • DOW THEORY: FORECASTS.  // Dow Theory Forecasts;9/8/2008, Vol. 64 Issue 36, p9 

    The article offers information on the Forecasts' Monitored List supplement in September 2008. The Monitored List supplement offers investment ratings and other key data on 199 monitored stocks. Moreover, stocks are ranked with five terms such as Focus Buys, Buys, Long-Term Buys, Neutrals and...

  • HHGregg Inc.  // Indianapolis Business Journal;8/20/2012, Vol. 33 Issue 25, p23A 

    The article profiles electronics and home appliances retailer HHGregg Inc. in Indianapolis, Indiana. It details the company's market value of common shares and revenue for the fiscal quarter ending June 30, 2012. It also presents the company directors, its major stockholders, and a list of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics